Research Progress of IL-17A Antibody Drugs in Inflammation and Cancer Therapy
PENG Shanshan, MEI Shengsheng, LIANG Keying, ZHAN Jinbiao*
IL-17A (interleukin-17A) is a key pro-inflammatory factor mainly secreted by Th17 cells (T helper 17 cells). After binding with receptors, it activates downstream signaling pathways and induces the secretion of a variety of cytokines and chemokines. Importantly, IL-17A plays a significant role in the occurrence and development of autoimmune diseases, hypersensitivity and malignant tumors. Multiple IL-17A monoclonal antibodies have been approved for the clinical treatment of inflammatory diseases. This review describes the progress of IL-17A antibodies in the treatment of inflammation and cancer, and analyzes the challenge and development trends of them.
CN
EN